Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Precocious Puberty Treatment & Management

  • Author: Paul B Kaplowitz, MD, PhD; Chief Editor: Stephen Kemp, MD, PhD  more...
 
Updated: Jun 24, 2016
 

Surgical Care

When central precocious puberty (CPP) is caused by a CNS tumor other than a hamartoma, a resection should be attempted to the extent possible without impinging on vital structures such as the optic nerves. Radiation therapy is often indicated if surgical resection is incomplete. Unfortunately, removal of the tumor rarely causes regression of precocious puberty.

Next

Medical Care

Patients treated with GnRH agonists

For patients with precocious puberty treated with gonadotropin-releasing hormone (GnRH) agonists:

  • Follow up every 4-6 months to ensure that progression of puberty has been arrested.
  • Favorable signs include normalization of accelerated growth, reduction (or at least no increase) in size of breasts, and suppression of gonadotropin levels after a challenge of GnRH.
  • The ideal testing frequency has not been established. A suggested timeline for girls is to obtain a GnRH test about 4 months after starting the drug to confirm suppression and then no more often than yearly, as long as clinical indicators suggest that the drug is working as intended. Some clinicians advocate dispensing with formal GnRH testing as long as growth has slowed and breasts have decreased in size. In boys, a decrease in the size of the testes and a fall in serum testosterone level to less than 20 ng/dL are good indications of efficacy.
  • Monitor bone age yearly to confirm that the rapid advancement seen in the untreated state has slowed, typically to a half year of bone age per year or less.

A literature review by Liu et al indicated that in girls with idiopathic central precocious puberty, treatment with a combination of GnRH analogue and growth hormone leads to better height results than does therapy with GnRH analogue alone while apparently causing no severe adverse effects.[29]

Similarly, a literature review by Wang et al found that the addition of recombinant human growth hormone to GnRH agonist therapy resulted in significant height increase, as well as increases in predicted adult height and height standard deviation for bone age, in children with central precocious puberty. Efficacy was greater in patients whose initial treatment began prior to age 10 years or whose therapy lasted more than 12 months.[30]

Patients not treated with GnRH agonists

In many cases, the physician may elect to observe the child with central precocious puberty (CPP), either because the age is borderline (ie, 7-8 y) and the child and family are coping well or because the progression of puberty is not rapid and the bone age is only mildly advanced (ie, ≤ 1 y), so that predicted adult height falls well within the reference range. In these cases, follow-up at 6-month intervals is appropriate. Testing and treatment may be initiated if the tempo of puberty begins to accelerate and predicted adult height deteriorates.

Previous
 
 
Contributor Information and Disclosures
Author

Paul B Kaplowitz, MD, PhD Professor of Pediatrics, George Washington University School of Medicine and Health Sciences; Chief of Endocrinology, Children's National Medical Center

Paul B Kaplowitz, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Diabetes Association, Endocrine Society, Pediatric Endocrine Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Lynne Lipton Levitsky, MD Chief, Pediatric Endocrine Unit, Massachusetts General Hospital; Associate Professor of Pediatrics, Harvard Medical School

Lynne Lipton Levitsky, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Diabetes Association, American Pediatric Society, Endocrine Society, Pediatric Endocrine Society, Society for Pediatric Research

Disclosure: Received grant/research funds from Eli Lilly for pi; Received grant/research funds from NovoNordisk for pi; Received consulting fee from NovoNordisk for consulting; Partner received consulting fee from Onyx Heart Valve for consulting.

Chief Editor

Stephen Kemp, MD, PhD Former Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Arkansas for Medical Sciences College of Medicine, Arkansas Children's Hospital

Stephen Kemp, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Pediatric Society, Endocrine Society, Phi Beta Kappa, Southern Medical Association, Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

Phyllis W Speiser, MD Chief, Division of Pediatric Endocrinology, Steven and Alexandra Cohen Children's Medical Center of New York; Professor of Pediatrics, Hofstra-North Shore LIJ School of Medicine at Hofstra University

Phyllis W Speiser, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, Endocrine Society, Pediatric Endocrine Society, Society for Pediatric Research

Disclosure: Nothing to disclose.

References
  1. Chalumeau M, Chemaitilly W, Trivin C, et al. Central precocious puberty in girls: an evidence-based diagnosis tree to predict central nervous system abnormalities. Pediatrics. 2002 Jan. 109(1):61-7. [Medline]. [Full Text].

  2. Ng SM, Kumar Y, Cody D, et al. Cranial MRI scans are indicated in all girls with central precocious puberty. Arch Dis Child. 2003 May. 88(5):414-8; discussion 414-8. [Medline]. [Full Text].

  3. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969 Jun. 44(235):291-303. [Medline].

  4. Herman-Giddens ME, Slora EJ, Wasserman RC, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. Pediatrics. 1997 Apr. 99(4):505-12. [Medline]. [Full Text].

  5. [Guideline] Kaplowitz PB, Oberfield SE. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Pediatrics. 1999 Oct. 104(4 Pt 1):936-41. [Medline]. [Full Text].

  6. Biro FM, Galvez MP, Greenspan LC, Succop PA, Vangeepuram N, Pinney SM. Pubertal assessment method and baseline characteristics in a mixed longitudinal study of girls. Pediatrics. 2010 Sep. 126(3):e583-90. [Medline].

  7. Sorensen K, Aksglaede L, Petersen JH, Juul A. Recent changes in pubertal timing in healthy Danish boys: associations with body mass index. J Clin Endocrinol Metab. 2010 Jan. 95(1):263-70. [Medline].

  8. Parent AS, Teilmann G, Juul A, et al. The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends, and changes after migration. Endocr Rev. 2003 Oct. 24(5):668-93. [Medline]. [Full Text].

  9. Aksglaede L, Sorensen K, Petersen JH, et al. Recent decline in age at breast development: the Copenhagen Puberty Study. Pediatrics. 2009 May. 123(5):e932-9. [Medline].

  10. Ma HM, Du ML, Luo XP, et al. Onset of breast and pubic hair development and menses in urban Chinese girls. Pediatrics. 2009 Aug. 124(2):e269-77. [Medline].

  11. Teilmann G, Petersen JH, Gormsen M, Damgaard K, Skakkebaek NE, Jensen TK. Early puberty in internationally adopted girls: hormonal and clinical markers of puberty in 276 girls examined biannually over two years. Horm Res. 2009. 72(4):236-46. [Medline].

  12. Wu T, Mendola P, Buck GM. Ethnic differences in the presence of secondary sex characteristics and menarche among US girls: the Third National Health and Nutrition Examination Survey, 1988-1994. Pediatrics. 2002 Oct. 110(4):752-7. [Medline]. [Full Text].

  13. Bridges NA, Christopher JA, Hindmarsh PC, Brook CG. Sexual precocity: sex incidence and aetiology. Arch Dis Child. 1994 Feb. 70(2):116-8. [Medline].

  14. Walvoord EC, Mazur T. Behavioral problems and idiopathic central precocious puberty: Fact or fiction?. Pediatr Endocrinol Rev. June 2007. 4 (suppl 3):306-12.

  15. Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab. 2007 Sep. 92(9):3483-9. [Medline].

  16. [Guideline] American Academy of Pediatrics. Sexuality education for children and adolescents: Committee on Psychosocial Aspects of Child and Family Health and Committee on Adolescence. Pediatrics. 2001 Aug. 108(2):498-502.

  17. de Vries L, Kauschansky A, Shohat M, Phillip M. Familial central precocious puberty suggests autosomal dominant inheritance. J Clin Endocrinol Metab. 2004 Apr. 89(4):1794-800. [Medline]. [Full Text].

  18. Mamun AA, Hayatbakhsh MR, O'Callaghan M, Williams G, Najman J. Early overweight and pubertal maturation--pathways of association with young adults' overweight: a longitudinal study. Int J Obes (Lond). 2009 Jan. 33(1):14-20. [Medline].

  19. Frisch RE, McArthur JW. Menstrual cycles: fatness as a determinant of minimum weight for height necessary for their maintenance or onset. Science. 1974 Sep 13. 185(4155):949-51. [Medline].

  20. Lee JM, Appugliese D, Kaciroti N, et al. Weight status in young girls and the onset of puberty. Pediatrics. 2007 Mar. 119(3):e624-30. [Medline].

  21. Currie C, Ahluwalia N, Godeau E, Nic Gabhainn S, Due P, Currie DB. Is Obesity at Individual and National Level Associated With Lower Age at Menarche? Evidence From 34 Countries in the Health Behaviour in School-aged Children Study. J Adolesc Health. 2012 Jun. 50(6):621-6. [Medline].

  22. Reiter EO, Saenger P. Premature adrenarche. The Endocrinologist. 1997. 7:85-88.

  23. Stephen MD, Jehaimi CT, Brosnan PG, Yafi M. Sexual precocity in a 2-year-old boy caused by indirect exposure to testosterone cream. Endocr Pract. 2008 Nov. 14(8):1027-30. [Medline].

  24. Armengaud JB, Charkaluk ML, Trivin C, Tardy V, Bréart G, Brauner R. Precocious pubarche: distinguishing late-onset congenital adrenal hyperplasia from premature adrenarche. J Clin Endocrinol Metab. 2009 Aug. 94(8):2835-40. [Medline].

  25. Resende EA, Lara BH, Reis JD, Ferreira BP, Pereira GA, Borges MF. Assessment of basal and gonadotropin-releasing hormone-stimulated gonadotropins by immunochemiluminometric and immunofluorometric assays in normal children. J Clin Endocrinol Metab. 2007 Apr. 92(4):1424-9. [Medline].

  26. Houk CP, Kunselman AR, Lee PA. Adequacy of a single unstimulated luteinizing hormone level to diagnose central precocious puberty in girls. Pediatrics. 2009 Jun. 123(6):e1059-63. [Medline].

  27. [Guideline] Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009 Apr. 123(4):e752-62. [Medline].

  28. Sathasivam A, Garibaldi L, Shapiro S, Godbold J, Rapaport R. Leuprolide Stimulation Testing for the Evaluation of Early Female Sexual Maturation. Clin Endocrinol (Oxf). 2010 Feb 23. [Medline].

  29. Liu S, Liu Q, Cheng X, Luo Y, Wen Y. Effects and safety of combination therapy with gonadotropin-releasing hormone analogue and growth hormone in girls with idiopathic central precocious puberty: a meta-analysis. J Endocrinol Invest. 2016 May 25. [Medline].

  30. Wang M, Zhang Y, Lan D, Hill JW. The Efficacy of GnRHa Alone or in Combination with rhGH for the Treatment of Chinese Children with Central Precocious Puberty. Sci Rep. 2016 Apr 13. 6:24259. [Medline]. [Full Text].

  31. Fuld K, Chi C, Neely EK. A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty. J Pediatr. 2011 Dec. 159(6):982-7.e1. [Medline].

  32. Eugster EA, Clarke W, Kletter GB, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab. 2007 May. 92(5):1697-704. [Medline].

  33. Kaplowitz P. Clinical characteristics of 104 children referred for evaluation of precocious puberty. J Clin Endocrinol Metab. 2004 Aug. 89(8):3644-50. [Medline]. [Full Text].

  34. Kaplowitz P. Precocious puberty: update on secular trends, definitions, diagnosis, and treatment. Adv Pediatr. 2004. 51:37-62. [Medline].

  35. Kaplowitz PB, Slora EJ, Wasserman RC, et al. Earlier onset of puberty in girls: relation to increased body mass index and race. Pediatrics. 2001 Aug. 108(2):347-53. [Medline]. [Full Text].

  36. Kletter GB, Kelch RP. Clinical review 60: Effects of gonadotropin-releasing hormone analog therapy on adult stature in precocious puberty. J Clin Endocrinol Metab. 1994 Aug. 79(2):331-4. [Medline].

  37. Lee PA. Laboratory monitoring of children with precocious puberty. Arch Pediatr Adolesc Med. 1994 Apr. 148(4):369-76. [Medline].

  38. Neely EK, Wilson DM, Lee PA, et al. Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty. J Pediatr. 1995 Jul. 127(1):47-52. [Medline].

  39. Pescovitz OH, Comite F, Hench K, et al. The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy. J Pediatr. 1986 Jan. 108(1):47-54. [Medline].

  40. Junqueira FR, Lara LA, Martins WP, Ferriani RA, Rosa-E-Silva AC, et al. Gonadotropin and Estradiol Levels after Leuprolide Stimulation Tests in Brazilian Girls with Precocious Puberty. J Pediatr Adolesc Gynecol. 2015 Oct. 28 (5):313-6. [Medline].

  41. Iannetta R, Melo AS, Iannetta O, Marchini JS, Paula FJ, et al. Use of a Gonadotropin-releasing Hormone Analog to Treat Idiopathic Central Precocious Puberty Is Not Associated with Changes in Bone Structure in Postmenarchal Adolescents. J Pediatr Adolesc Gynecol. 2015 Oct. 28 (5):304-8. [Medline].

  42. Catlı G, Erdem P, Anık A, Abacı A, Bober E. Clinical and laboratory findings in the differential diagnosis of central precocious puberty and premature thelarche. Turk Pediatri Ars. 2015 Mar. 50 (1):20-6. [Medline].

 
Previous
Next
 
Graph represents the prevalence of breast development at Tanner stage 2 or greater by age and race.
Graph represents the prevalence of pubic hair at Tanner stage 2 or greater by age and race.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.